Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (246)	1/28/2003 3:36:17 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

SUPG Is up 15.07% on volume of 119 K (still below its daily average.) The stock almost made a double bottom yesterday with its L of Dec.27 (2.60 and yesterday' L 2.69), but that is the level from which it spurted 40% on Dec.30, when I made the comment on the Biotech fireworks thread.<g> Message 18382668 The company has not made any further announcements,(to my knowledge)since December 30 when it submitted a preliminary NDA for Orathecin, its oral chemotherapy treatment for patients with pancreatic Ca. The drug had received fast-track designation by the FDA in November In December SUPG said that it expects to have the complete NDA submitted by the end of the 1st Q of 2003.( The company has a Phase III with more than 2,700 patients.) The insiders only hold around 6% of the shares outright, but reportedly have done some buying lately and the institutioon that hold around 30% of the shares have done some more significant buying. The company is somewhat stranded for cash.(At its present burn rate has enough money to go for one or two Qs without further financing.<g>)So it certainly seems to need a fast approval of Orathecin. bigcharts.marketwatch.com Bernard